Forbion and Goldman Sachs Alternatives led a $372m Series D round in MapLight Therapeutics.

Forbion and Goldman Sachs Alternatives led a $372m Series D round in MapLight Therapeutics, a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system, with participation from Sanofi, T. Rowe Price, Avego BioScience Capital, Novo Holdings, 5AM Ventures and Blue Owl. With this financing, MapLight will advance ML-007C-MA through ongoing Phase 2 trials for schizophrenia and Alzheimer’s disease psychosis. The financing will also fund the exploration of other potential indications for ML-007C-MA, as well as the continued advancement of other clinical and preclinical pipeline programs.